Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.
Source: www.fool.com
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.